Day One Biopharmaceuticals

Day One Biopharmaceuticals is a developer of novel cancer drugs for children. The company’s DAY101 is a highly selective oral pan-RAF small molecule inhibitor that can be developed to treat cancer patients of all ages. The RAS-RAF-MEK-ERK pathway is a crucial signaling pathway that regulates key cellular functions such as growth and survival. This pathway is one of the most commonly mutated oncogenic pathways in cancer. Genomic alterations in BRAF can lead to constitutive pathway activation, thereby driving tumor growth.